Johnson & Johnson Plans $1 Billion Cell Therapy Plant in Pennsylvania, Creating 500 Biomanufacturing and 4,000 Construction Jobs
Johnson & Johnson plans to invest $1bn to build a cell and gene therapy manufacturing plant in Montgomery County, Pennsylvania, creating over 500 biomanufacturing and 4,000 construction jobs. It joins J&J’s $55bn expansion program to support Carvykti, which generated $1.9bn in FY2025 and is projected to reach $7.8bn by 2031.
1. Pennsylvania Cell Therapy Facility
Johnson & Johnson has selected Montgomery County, Pennsylvania, for a $1 billion cell and gene therapy manufacturing site. Once operational, it will employ over 500 skilled biomanufacturing professionals and generate approximately 4,000 construction positions during its build.
2. Carvykti Production Capacity
The new site will bolster manufacturing capacity for Carvykti (ciltacabtagene autoleucel), which posted $1.9 billion in global sales in FY2025 and is forecast to reach $7.8 billion by 2031.
3. Broader US Expansion Initiative
This plant is part of J&J’s $55 billion initiative to onshore production, including a $2 billion biologics facility in North Carolina and a planned drug product site. The company also secured a Most Favored Nation deal to avoid import tariffs, reflecting a strategic shift toward domestic manufacturing.